The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

ISSN: 2212-4039 (Online)
ISSN: 1872-2113 (Print)


Volume 9, 3 Issues, 2015


Download PDF Flyer




Recent Patents on Drug Delivery & Formulation

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ryan F. Donnelly
School of Pharmacy
Queen's University Belfast
Belfast
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

Author(s): Irina Kadiyala and Dylan Jacobs

Affiliation: Vertex Pharmaceuticals Incorporated, Department of Formulation Development, 130 Waverly St., Cambridge, MA 02139-4242.

Abstract

This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.

Keywords: Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 8
Issue Number: 1
First Page: 3
Last Page: 11
Page Count: 9
DOI: 10.2174/18722113113079990014
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science